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The increasing burden of chronic kidney disease worldwide and recent advance-
ments in the understanding of pathologic events leading to kidney injury have
opened up new potential avenues for therapies to further diminish progression of
kidney disease by targeting the glomerular ﬁltration barrier and reducing protei-
nuria. The glomerular ﬁltration barrier is affected by many different metabolic and
immune-mediated injuries. Glomerular endothelial cells, the glomerular basement
membrane, and podocytes—the three components of the ﬁltration barrier—work
together to prevent the loss of protein and at the same time allow passage of water
and smaller molecules. Damage to any of the components of the ﬁltration barrier
can initiate proteinuria and renal ﬁbrosis. Transforming growth factor-beta (TGF-b)
is a pleiotropic cytokine strongly associated with the ﬁbrogenic response. It has a
known role in tubulointerstitial ﬁbrosis. In this review we will highlight what is
known about TGF-b and how it interacts with the components of glomerular
ﬁltration barrier and causes loss of function and proteinuria.
& 2013. The Korean Society of Nephrology. Published by Elsevier. This is an open
access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Proteinuria is a common ﬁnding in many kidney diseases such
as diabetic nephropathy and chronic glomerulonephritis. Elevated
urine protein is strongly associated with glomerulosclerosis,
interstitial ﬁbrosis, and progression of chronic kidney disease
[1], and independently predicts worse clinical outcomes [2]. Most
agents that reduce proteinuria have beneﬁcial effects on long-
term renal function [3]. Despite widespread use of drugs that
decrease proteinuria, progression to end-stage kidney disease
remains all too common.
Traditionally, our understanding of the pathogenesis of
proteinuria focused on glomerular hypertension. Effective
treatment has been aimed at the renin–angiotensin system,rean Society of Nephrology. P
ses/by-nc-nd/4.0/).
ine, McMaster
’s Hospital, 50 Charlton
rgetts).which reduces intraglomerular pressure [4]. Over the past
decade, interest has shifted from this mechanical view to a
cellular and molecular perspective. The glomerular ﬁltration
barrier consists of endothelial cells, a basement membrane,
and a specialized epithelial cell—the podocyte (Fig. 1). Dys-
function in any component of the glomerular ﬁltration barrier
can lead to proteinuria. Increasingly, it has been recognized
that there is a basal cross-talk between the endothelium and
the podocytes, mainly involving angiogenic molecules such as
vascular endothelial growth factor (VEGF) that maintain the
health of the ﬁltration barrier [5]. Perturbation of this signal-
ing can lead to endothelial cell or podocyte injury. Podocyte
injury manifests as retraction of the podocyte foot processes
leading to effacement, loss of slit diaphragm proteins [6],
dedifferentiation, detachment, and apoptosis [7]. Podocyte
de-differentiation has been described as a process similar to
epithelial to mesenchymal transition (EMT) and has been
shown to occur in response to transforming growth factor-beta
(TGF-b) [8].ublished by Elsevier. This is an open access article under the CC BY-NC-
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Figure. 1. Structure of the glomerular ﬁltration barrier. (A) Electron micrograph of a normal rat glomerulus showing the basic structures of the
ﬁltration barrier. (B) A rat glomerulus 7 days after exposure in vivo to an adenovirus expressing active transforming growth factor-beta (TGF-b)
demonstrates podocyte de-differentiation and foot process effacement which results in proteinuria. An adenovirus expressing active TGF-b was
infused via the left renal artery in Sprague Dawley rats. Gene expression was conﬁrmed by measuring urinary TGF-b protein. Foot process
effacement was quantiﬁed, as was expression of nephrin and synaptopodin. These features suggested podocyte dedifferentiation [37].
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Many common kidney diseases such as diabetes and chronic
glomerulonephritis ﬁrst manifest with structural glomerular
injury and proteinuria [9] followed by tubulointerstitial ﬁbrosis
[10]. Proteinuria is a prognostic indicator in a variety of kidney
diseases. In a large cohort study, Hemmelgarn et al. [2] demon-
strated that the presence of even mild proteinuria (trace to 1þ
on urine dipstick or 30–300 mg/g albumin to creatinine ratio)
increased the risk of mortality and progressive renal failure
independently of baseline renal function and other prognostic
markers. Proteinuria is a common condition with signiﬁcant
implications with respect to population health. In the National
Health and Nutrition Examination Survey study, 8.2% of the
general US population have mild proteinuria, and 1.1% have
overt proteinuria [11].
Although proteinuria is strongly linked epidemiologically
to progressive chronic kidney disease, there is ongoing debate
as to whether proteinuria is causally linked to tubulointer-
stitial ﬁbrosis. When renal tubular cells are grown in culture
and exposed to high levels of protein, the cells express
inﬂammatory and ﬁbrogenic cytokines [12]. These in vitro
ﬁndings are supported by evidence from animal models
where protein overload alone induces chronic renal injury
[13]. Other hypothesized mechanisms to explain progressive
interstitial ﬁbrosis after glomerular injury include loss of
peritubular capillaries and tubular hypoxia [14,15], ﬁltered
cytokines [13], misdirected ﬁltrate from sclerosed glomeruli
[14], and interstitial inﬂammation [15].
Although there is some disagreement [16], the prevalent
paradigm is that proteinuria is primarily a result of dysfunc-
tion of the glomerular ﬁltration apparatus with a special focus
on the podocyte. The podocyte is a terminally differentiated
epithelial cell with a highly specialized structure that consists
of foot processes that wrap around the glomerular capillaries.
A series of transmembrane proteins link the foot processes,
and comprise the ‘slit diaphragm’ structure that is crucial to
proper function of this barrier [6].
If podocytes are injured, the expression of the slit dia-
phragm proteins decreases. For example, in diabetic nephropathy,the expression of nephrin decreases [17] and nephrin appears in
the urine [18]. Later in the course of glomerular disease,
podocytes detach from the basement membrane and also are
found in the urine [19,20]. Podocyte apoptosis is also a common
ﬁnding in advanced glomerular injury [21].Communication between components of the ﬁltration
barrier
It is increasingly clear that components of the glomerular
ﬁltration barrier interact with each other directly or through
paracrine mediators (Fig. 2). For example, podocytes secrete
vascular growth factors that maintain glomerular endothelial
health [22]. Elevated levels of podocyte derived VEGF leads to
a collapsing glomerulopathy, whereas decreased VEGF leads
to endotheliosis (endothelial swelling and ﬁbrin deposition)
[22]. An anti-VEGF antibody used commonly in bowel and
renal cancer has been shown to increase the risk for protei-
nuria and hypertension [23], suggesting a direct clinical effect
of altering the podocyte/endothelial cell interaction.
Glomerular endothelial cells show evidence of dysfunction
at an early stage of glomerular injury [24] and secrete TGF-b
in response to VEGF stimulation [25]. Paracrine interaction
between endothelium and podocytes involves other angiogenic
factors such as angiopoietin- (ANGPT) 1 [26] and ANGPT-2 [27].
These are secreted by podocytes and impact on endothelial cells.
Although not directly part of the glomerular ﬁltration appa-
ratus, mesangial cells play an important role in paracrine signal-
ing. Mesangial cells respond to high glucose [28] and pathogenic
immunoglobulin A (IgA) [29] by secreting TGF-b. Khan et al. [30]
have shown that mesangial cells can have a protective effect.
TGF-b bound to the integrin avb8 is sequestered on mesangial
cell membrane. When b8 integrin was knocked out, they
observed higher levels of bioactive TGF-b, which resulted in
endothelial cell apoptosis and proteinuria [30]. Mesangial cells
also produce other paracrine signals such as stromal-derived
factor-1, which affects podocyte function [31].
Integrins play a role in the interaction between podocytes
and the glomerular basement membrane (GBM). Integrin
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GBM. Interruption of this interaction leads to podocyte loss
and glomerulosclerosis [32].
Role of angiopoietins in proteinuria
Angiopoietins are known to modify the effects of VEGF [33].
In quiescent vasculature, ANGPT1 is produced by perivascular
cells and has a paracrine effect on endothelial cells. ANGPT1
binds to its receptor, tyrosine endothelial kinase (TEK), and
signals through phosphatidylinositol-4,5 bisphosphate 3-kinase
(PI3K)/Akt to maintain vascular integrity [34]. ANGPT2 similarly
binds to the TEK receptor and is thought to be an antagonist for
ANGPT1. In pathologic settings, VEGF and ANGPT2 are upregu-
lated and lead to vascular destabilization, angiogenic sprouting,
and new vessel formation [35]. In the quiescent glomerulus,
ANGPT1 and VEGF are produced by podocytes and have
protective and antiproteinuric effects on endothelial cells [26].
ANGPT2 has been associated with proteinuria and renal
injury in several settings, including lupus nephritis [36] and
diabetic nephropathy [4]. In previous work, Davis et al. [27]
created a mouse model where ANGPT2 was overexpressed by
a podocyte speciﬁc promoter. In this model, ANGPT2 over-
expression led to proteinuria and decreased podocyte nephrin
expression. The authors did not describe podocytes foot
process effacement in response to ANGPT2, but they demon-
strated endothelial cell dysfunction which was believed to
underlie the proteinuric response.
In a recently described model of TGF-b overexpression
in the glomerulus using an adenovirus [37], we found that
ANGPT1 and ANGPT2 were both upregulated in the glomeruli
from animals exposed to AdTGFB1, which is similar to
observations by Campean et al. [38] in the Thy 1.1 model
of glomerular injury. In unstimulated podocytes, we found
no expression of TEK, but exposure to TGF-b increased
TEK expression. We were able to block the effects of TGF-bEndothelial cell  
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Figure. 2. Effect of transforming growth factor-beta (TGF-b) on the glom
podocytes with their intracellular slit diaphragm proteins, the glomerular
glycocalyx. Podocytes bind to the GBM through integrins. Podocytes expre
(VEGF) and angiopoietins (ANGPT). Podocyte-derived VEGF and ANGPT1 ac
barrier. TGF-b is produced by endothelial cells in response to increased VE
concentration of glucose. TGF-b affects all structures of the ﬁltration bar
production. TGF-b induces an EMT-like phenomenon in the podocyte with lo
of mesenchymal proteins. We have demonstrated a role for TGF-b in the in
ANGPT receptor tyrosine endothelial kinase TEK that is responsible for somon podocytes in culture with small interfering RNA directed
against TEK, or with antibodies directed against TEK or
ANGPT1. We hypothesized that TGF-b is required for podo-
cyte dedifferentiation either as a direct cofactor or through
the induction of TEK receptors on podocytes [37].Transforming growth factor-beta
Much more is known about TGF-b than was known in late
1970 s when De Larco and Todaro [39] considered it a ‘‘factor’’
responsible for changing a cell’s phenotype and called it
‘‘sarcoma growth factor’’. TGF-b has three isoforms in humans
[40]. TGF-b is ubiquitously expressed and all cell types and all
cells appear to respond to TGF-b [41]. In the glomerulus,
TGF-b is produced by the podocytes and mesangial cells [42].
TGF-b is bound to a latency-associated peptide and seques-
tered in the extracellular matrix. Activation of TGF-b B is a
complex and tightly regulated process [41,43]. The mechanism
of TGF-b activity at the cellular level is also complex, but the
SMAD proteins are key signaling molecules for TGF-b [44].
TGF-b is involved in proteinuria and glomerulosclerosis
TGF-b is associated with ﬁbrosis in many organ systems
[45] including the kidney, where it can be induced by
angiotensin [46], proteinuria [47], and hypoxia [48]. TGF-b
induces elaboration of extracellular matrix components.
Although controversial [49], TGF-b possibly induces EMT of
renal tubular cells [50,51]. Numerous studies have identiﬁed
TGF-b as being upregulated during the course of progressive
renal injury [52]. Similarly, inhibition of TGF-b has been
shown to ameliorate renal injury [53].
TGF-b is not only involved in ECM accumulation, ﬁbrosis,
and progressive renal impairment, but also plays a role in
changes to the glomerular ﬁltration barrier and inductionEffaced podocyte  
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latter observation. Urinary TGF-b correlates with the degree
of proteinuria [54]. Direct inhibition of TGF-b in models of
renal disease reduces proteinuria [55–57].
Proteinuria was described in three animal models of TGF-b
overexpression [58–60]. High levels of systemic TGF-b using
a transgenic mouse model were shown to induce proteinuria,
but the mechanism was not described [58]. Krag et al. [59]
described a novel transgenic mouse with TGF-b driven from
the Ren-1c promoter of the juxtaglomerular apparatus that
developed albuminuria [59]. Wang et al. [60] used a hydro-
dynamic gene transfer model to overexpress TGF-b in the
glomerulus and identiﬁed the role of Wnt/b-catenin in TGF-b-
induced proteinuria.TGF-b and podocyte dedifferentiation
The presence of the slit diaphragm as an important
component of the glomerular ﬁltration apparatus has been
known for more than 30 years. Over the past 15 years, key
molecular components of the slit diaphragm such as nephrin
have been identiﬁed [61], the loss of which is associated with
proteinuria [6]. Initially, this loss of epithelial markers was
termed ‘‘de-differentiation’’ [62], but work by Sam et al. [63]
later supported by Li et al. [8] identiﬁed that podocytes may
undergo EMT in response to TGF-b.
Podocyte dedifferentiation is an early event in glomerular
injury, whereas subsequent podocyte apoptosis and sloughing
has been observed in advanced renal disease [7]. Notably,
apoptosis appears to be a later ﬁnding that occurs after the
onset of proteinuria [21]. Podocyte cell death is a complex
process involving not only apoptosis, but also anoikis, autop-
hagy, and, in some cases, necrosis [64].
Several pathways and growth factors are involved in this
EMT process. As mentioned, TGF-b has been shown to induce
podocyte EMT in vitro [8,63,65]. SNAIL is one of a family of
zinc ﬁnger regulatory proteins shown to be an important
mediator of EMT [66] and has been shown to suppress
nephrin gene transcription in a model of puramycin-induced
nephrosis [67]. Other pathways shown to be involved in
podocyte EMT include mammalian target of rapamycin
(mTOR) [68,69], glycogen synthase kinase 3 b (GSK3B) [70],
b-catenin [71], integrin-linked kinase (ILK) [72], and Notch
[73]. PI3K has also been shown to be a key regulator of
podocyte EMT, and PI3K inhibition was shown to block
podocyte injury in an in vitro IgA model [74]. Recently, Finer
et al. [75] have shown that podocyte injury induced by
Adriamycin is mostly mediated by PI3K, and TGF-b is not
involved in this process, but is involved in a delayed, ﬁbro-
genic response.
Notch is proving to be a key regulator of podocyte injury
and apoptosis. Notch is a transmembrane receptor protein. On
ligand binding, Notch undergoes a series of modiﬁcations
including intracellular cleavage by gamma secretase [76]. The
intracellular Notch fragment then acts as a transcriptional
regulator. Notch interacts with the b-catenin and Wnt path-
ways during development of the kidney, but is quiescent in the
adult kidney. During injury, TGF-b increases expression of the
Notch ligand Jagged 1 and thus induces Notch signaling. In a
seminal paper, Niranjan et al. [77] showed that overexpression
of the intracellular Notch fragment in podocytes leads to
severe proteinuria, glomerulosclerosis, and podocyte apoptosis.Using a gamma secretase inhibitor to block Notch signaling,
renal injury could be reduced in a rodent model [77].
TGF-b mainly employs SMAD proteins to translate its
signal; however, other signaling pathways have been shown
to be activated by TGF-b. We have shown that in peritoneal
mesothelial cells, EMT still occurs in mice lacking SMAD3,
suggesting that non-SMAD pathways are critical for EMT [78].
This is supported by the observation of Wang et al. [79], who
observed ongoing proteinuria and foot process effacement in
SMAD3–/– mice rendered diabetic. The SMAD3–/– mice were
protected from glomerulosclerosis and renal dysfunction.
EMT has been observed in urinary podocytes in patients
with diabetes [80]. Although understanding podocyte EMT
will provide valuable insights into the mechanisms of early
glomerular injury progressive kidney disease, there are also
therapeutic implications. For example, it has been demon-
strated that TGF-b antagonists, speciﬁcally bone morphoge-
netic protein 7, can reverse EMT changes in renal tubular
epithelium [50] and podocytes [81].
TGF-b and glomerular endothelial cells
Research into the biology of glomerular endothelial cells
has perhaps been overshadowed by a strong interest in the
podocyte. Early research suggested that the size of endothelial
cells fenestrations is much larger than most plasma proteins
(60–100 nm) and thus the endothelium should not form
a signiﬁcant ﬁltration barrier. More recent work identi-
ﬁed the importance of the glycocalyx, a dense negatively
charged protein complex, as an important component of the
glomerular ﬁltration barrier [82]. Any injury that perturbs the
integrity of this glycocalyx may lead to proteinuria [83].
Podocyte-derived VEGF has direct action on glomerular
endothelial cells including proliferation and production of TGF-b
[25]. VEGF also appears to regulate endothelial fenestrations [22].
Endothelial fenestrations were decreased in a biopsy study of
Pima Indians with diabetes [19]. This decreased endothelial
fenestration correlated with decreased glomerular ﬁltration and
increased albuminuria, whereas podocyte loss correlated with
albumin excretion alone. There has been a direct association
observed between podocyte injury and endothelial injury possibly
mediated by loss of podocyte VEGF excretion [84].
Glomerular endothelial cells also respond to angiopoietins.
Satchell et al. [26] have demonstrated that glomerular endo-
thelial cells express the angiopoietin receptor TEK. In this
study, ANGPT1 decreased protein passage through endothelial
cell monolayers. As mentioned previously, overexpression
of ANGPT2 in podocytes led to endothelial apoptosis and
proteinuria [27]. El-Banawy et al. [85] measured ANGPT2 in
patients with lupus and found that serum concentration
correlated with proteinuria and disease severity.
A recently identiﬁed mechanism by which TGF-b induces
endothelial cell dysfunction is endothelial to mesenchymal
transition [86]. This is a similar biological process to EMT, and
involves many of the same initiating factors and signaling
pathways [86]. These transitioned endothelial cells are
demonstrated to be the source of interstitial ﬁbrosis in three
well-known mouse models [87]. Although there is reasonable
evidence that endothelial mesenchymal transition plays a role
in interstitial ﬁbrosis, few studies have evaluated glomerular
endothelial cells. In one such study of streptozotocin-induced
diabetic nephropathy, Li et al. [88] used an endothelial
lineage traceable transgenic mouse to show that endothelial
Ghayur and Margetts / TGF-b and the glomerular ﬁltration barrier 7mesenchymal transition does occur in glomerular endothelial
cells. However, this observation predated the onset of protei-
nuria in this model, so the authors thought that endothelial
transition may play a role in glomerulosclerosis, but not
proteinuria. This same study identiﬁed TGF-b as an in vitro
mediator of endothelial mesenchymal transition [88].
TGF-b and the GBM
The GBM is a unique structure composed of laminin, type IV
collagen, nidogen, and heparan sulfate proteoglycan. Both podo-
cytes and endothelial cells have a role in development and
maintenance of this structure [89]. Early changes in diabetic
nephropathy include thickening of the GBM [90]. Krag et al. [91]
have shown that mild hyperglycemia alone does not affect the
GBM, but combined hyperglycemia and overexpression of TGF-b
leads to pronounced GBM thickening. Wang et al. [79] found
that the diabetes-induced GBM thickening was attenuated in
mice deﬁcient in the TGF-b signaling protein SMAD3.
The GBM is clearly an integral component of the glomer-
ular ﬁltration barrier; several genetic diseases that manifest
as proteinuria have defects in proteins expressed in the GBM
[89]. The structure and composition of the GBM can be altered
by TGF-b, and this can potentially lead to further changes in
the glomerular ﬁltration barrier and proteinuria.Therapeutic signiﬁcance
The evidence implicating TGF-b B in the induction of
proteinuria, glomerulosclerosis, and renal ﬁbrosis is compelling.
This makes TGF-b an important target in the prevention of
progressive renal disease. Direct inhibition of TGF-b is a poten-
tial therapeutic strategy and a recent Phase 1 clinical trial of an
anti-TGF-b antibody showed that a single infusion of this agent
was well tolerated [92].
Many conditions that lead to end stage kidney disease are
chronic processes that would necessitate long term inhibition
of TGF-b. TGF-b is pleiotropic and has roles in wound healing,
inﬂammation [93], and suppression of early cancers [94].
Long-term inhibition of TGF-b likely carries signiﬁcant risks.
Downstream pathways activated by TGF-b have become impor-
tant therapeutic targets. For example, connective tissue growth
factor is induced by TGF-b and is upregulated in patients with
diabetic nephropathy [95]. In a Phase I clinical trial, the anti-
connective tissue growth factor antibody FG-3019 was well
tolerated and demonstrated a signiﬁcant reduction in albumi-
nuria in patients with diabetic nephropathy [96].
Another potential downstream target of TGF-b is the mam-
malian target of rapamycin (mTOR). We have demonstrated
that mTOR is important in TGF-b -induced EMT, especially in
the absence of a SMAD3 signal [78]. Although associated with
increased risk of proteinuria in renal transplantation, recent
studies have suggested that low-dose mTOR inhibition may have
anti-proteinuric effects, at least in certain animal models [97].
TGF-b has been shown to activate the Wnt signaling pathway
in podocytes [60]. Blockade of Wnt signaling in vivo blocked
downstream signals involved in EMT such as SNAIL, and reduced
TGF-b induced urinary protein excretion. Canonical Wnt signal-
ing, through facilitation of b-catenin action, have been implicated
in ﬁbrosis of various organ systems [98] and treatment with a
compound that speciﬁcally inhibits b-catenin (ICG-001) has been
effective in animal models of lung and kidney ﬁbrosis [99,100].Increasingly, both genetic and epigenetic processes have
been identiﬁed in ﬁbrogenesis [101]. Micro RNAs (miRNAs)
are small, noncoding RNA fragments that modulate the
expression of other coding mRNAs. TGF-b has been shown
to increase the expression of miRNA 192 which then alters
downstream signaling events. Blocking miRNA has recently
been shown to have a beneﬁcial effect in a mouse model of
diabetic nephropathy [102]. Speciﬁcally, blocking miR-192
reduced albuminuria and renal ﬁbrosis.Summary
Proteinuria is a harbinger of progressive renal dysfunction
in a wide range of common kidney diseases. Even low levels of
proteinuria are associated with increased morbidity, mortality,
and progression to end-stage renal disease [2]. Therapies, such
as angiotensin pathway inhibitors, have been shown to reduce
proteinuria and slow down the progressive decline in renal
function. Despite this, further therapies are required. There
is increasing evidence that TGF-b plays an important role in
induction of proteinuria, along with subsequent glomerulo-
sclerosis and renal interstitial ﬁbrosis. Directly targeting TGF-b
is an exciting approach to chronic renal disease. Further
understanding of the TGF-b pathways involved will lead to
a range of novel therapies that will reduce proteinuria and
prevent progressive decline in renal function.Conﬂicts of interest
No conﬂict of interest.
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